Testicular Cancer, Version 2.2015.

Published

Journal Article

Germ cell tumors (GCTs) account for 95% of testicular cancers. Testicular GCTs constitute the most common solid tumor in men between the ages of 20 and 34 years, and the incidence of testicular GCTs has been increasing in the past 2 decades. Testicular GCTs are classified into 2 broad groups--pure seminoma and nonseminoma--which are treated differently. Pure seminomas, unlike nonseminomas, are more likely to be localized to the testis at presentation. Nonseminoma is the more clinically aggressive tumor associated with elevated serum concentrations of alphafetoprotein (AFP). The diagnosis of a seminoma is restricted to pure seminoma histology and a normal serum concentration of AFP. When both seminoma and elements of a nonseminoma are present, management follows that for a nonseminoma. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Testicular Cancer outline the diagnosis, workup, risk assessment, treatment, and follow-up schedules for patients with both pure seminoma and nonseminoma.

Full Text

Cited Authors

  • Motzer, RJ; Jonasch, E; Agarwal, N; Beard, C; Bhayani, S; Bolger, GB; Chang, SS; Choueiri, TK; Costello, BA; Derweesh, IH; Gupta, S; Hancock, SL; Kim, JJ; Kuzel, TM; Lam, ET; Lau, C; Levine, EG; Lin, DW; Michaelson, MD; Olencki, T; Pili, R; Plimack, ER; Rampersaud, EN; Redman, BG; Ryan, CJ; Sheinfeld, J; Shuch, B; Sircar, K; Somer, B; Wilder, RB; Dwyer, M; Kumar, R

Published Date

  • June 2015

Published In

Volume / Issue

  • 13 / 6

Start / End Page

  • 772 - 799

PubMed ID

  • 26085393

Pubmed Central ID

  • 26085393

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

International Standard Serial Number (ISSN)

  • 1540-1405

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2015.0092

Language

  • eng